Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22)

Leukemia volume 21, pages 836–837 (2007)Cite this article

In 2002, a t(4;22)(q12;q11) translocation fusing BCR to platelet-derived growth factor receptor-alpha (PDGFRA) was first reported in two patients with Philadelphia chromosome-negative (Ph-neg) chronic myelogenous leukemia (CML).1 Owing to the lack of imatinib, these patients underwent allogeneic stem cell transplantation. More recently, the same translocation was observed in two other patients with Ph-neg CML. Besides the inhibition of the aberrant BCR/ABL tyrosine kinase imatinib also affects other tyrosine kinases such as c-kit and the PDGFRs. Therefore, these patients received imatinib and achieved a hematologic and cytogenetic remission.2, 3 and 4

Here, we report on a third patient with a t(4;22)(q12;q11) who is in hematological, cytogenetic and molecular long-term remission following treatment with imatinib at a dose of 100 mg/day.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukemia fuses BCR to PDGFRA. Hum Mol Genet 2002; 11: 1391–1397.

    Article  CAS  Google Scholar 

  2. Krystal GW . Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leukemia Res 2004; 28: 53–59.

    Article  Google Scholar 

  3. Trempat P, Villalva C, Laurent G, Armstrong F, Delsol G, Dastugue N et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene 2003; 22: 5702–5706.

    Article  CAS  Google Scholar 

  4. Safley AM, Sebastian S, Collins TS, Tirado CA, Stenzel TT, Gong JZ et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosome Cancer 2004; 40: 44–50.

    Article  CAS  Google Scholar 

  5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.

    Article  CAS  Google Scholar 

  6. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20: 827–832.

    Article  CAS  Google Scholar 

  7. Selheim F, Holmsen H, Vassbotn FS . Platelet-derived growth factor inhibits platelet activation in heparinized whole blood. Thromb Res 1999; 95: 185–196.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. F Neumann and A Poelitz: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

    F Neumann, R Fenk, R Haas & U Germing

  2. Institute of Human Genetics and Anthropology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

    A Poelitz, B Hildebrandt & B Royer-Pokora

Authors
  1. F Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Poelitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Hildebrandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Fenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Royer-Pokora
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. U Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Neumann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neumann, F., Poelitz, A., Hildebrandt, B. et al. The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22). Leukemia 21, 836–837 (2007). https://doi.org/10.1038/sj.leu.2404557

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404557

Search

Advanced search

Quick links